FROM THE CEO & CHAIR OF THE BOARD

Dear Friends,

Every year, we are humbled to highlight the incredible progress made by the Lymphoma Research Foundation (LRF), which is only made possible through your generosity and belief in our mission to eradicate lymphoma and serve those touched by this disease.

As we reflect on 2022, we see a year in which our community and the Foundation were able to overcome challenges and make transformative progress. Still grappling with the impact of the COVID-19 pandemic, many patients and their caregivers relied upon the output of LRF’s COVID-19 and Lymphoma Panel. First convened in 2020 to inform the Foundation’s COVID-19 response, the Panel’s work has resulted in meaningful guidance and tangible patient programming, including our online COVID-19 Learning Center, which has become a critical tool for so many. Similarly, the LRF Helpline remains an important resource for the lymphoma community, serving more than 10,000 patients and caregivers last year alone.

Meghan Gutierrez Chief Executive Officer

Steven Eichberg Chair, Board of Directors

To expand our reach further, the Foundation launched a Spanish-language version of its website as a complement to its expert patient education resources through our Health Equity Initiative. And recognizing that patients learn in different ways and are increasingly using mobile health technology to manage their health, we were thrilled to release an updated version of our award-winning mobile app, Focus on Lymphoma.

The Foundation continues to fund a robust portfolio of cutting-edge research across every lymphoma subtype, and in 2022 LRF funded 29 research grants totaling nearly $6 million. This year’s report details our many grantees and the critical projects that would not be possible without your generous support.

In partnership with our expert Scientific Advisory Board, the Foundation was also able to harness its convening power to address important areas of unmet need. Through the preeminent Jaime Peykoff Follicular Lymphoma Initiative, LRF convened a first-of-its-kind scientific workshop to present data regarding newly approved and emerging treatments and discuss the best approaches for designing clinical trials and new therapeutic regimens. LRF also gathered a slate of international experts for its second Adolescent and Young Adult (AYA) Lymphoma Consortium and Scientific Workshop, continuing to lead the way in the investigation of those lymphomas which disproportionately impact young people. While much work remains, your partnership and dedication propel us into the new year. We remain as dedicated as ever to our shared goals and service to the more than one million Americans living with and surviving lymphoma.

Yours in partnership and progress,

Steven Eichberg Chair, Board of Directors

Meghan Gutierrez Chief Executive Officer